Cargando…

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

Recent failures in clinical trials for disease modification in Parkinson’s disease have highlighted the need for a non-human primate model of the synucleinopathy underpinning dopaminergic neuron degeneration. The present study was defined to begin the development of such a model in cynomolgus macaqu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koprich, James B., Johnston, Tom H., Reyes, Gabriela, Omana, Vanessa, Brotchie, Jonathan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130249/ https://www.ncbi.nlm.nih.gov/pubmed/27902767 http://dx.doi.org/10.1371/journal.pone.0167235

Ejemplares similares

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
por: Koprich, James B, et al.
Publicado: (2010)

Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies
por: Rcom-H'cheo-Gauthier, Alexandre N., et al.
Publicado: (2016)

Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies
por: Okita, Yuho, et al.
Publicado: (2017)

Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies
por: Javanshiri, Keivan, et al.
Publicado: (2022)

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
por: Koprich, James B., et al.
Publicado: (2011)

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
por: Visanji, Naomi P., et al.
Publicado: (2019)

Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
por: Sandoval, Ivette M., et al.
Publicado: (2021)

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies
por: Fairfoul, Graham, et al.
Publicado: (2016)

Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies
por: Kim, Jee Young, et al.
Publicado: (2019)

Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
por: Brás, Inês C., et al.
Publicado: (2021)

Viral alpha-synuclein knockdown prevents spreading synucleinopathy
por: Menon, Sindhu, et al.
Publicado: (2021)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies
por: Wu, Shenjie, et al.
Publicado: (2023)

Differential Effects of UCHL1 Modulation on Alpha-Synuclein in PD-Like Models of Alpha-Synucleinopathy
por: Cartier, Anna E., et al.
Publicado: (2012)

Hypoxic stress accelerates the propagation of pathological alpha‐synuclein and degeneration of dopaminergic neurons
por: Guo, Mengyuan, et al.
Publicado: (2022)

GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
por: Brockmann, Kathrin
Publicado: (2020)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
por: Just, Mie Kristine, et al.
Publicado: (2022)

Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models
por: Drobny, Alice, et al.
Publicado: (2023)

Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein
por: Chen, Yun-Hsiang, et al.
Publicado: (2021)

Alpha-Synuclein Disrupted Dopamine Homeostasis Leads to Dopaminergic Neuron Degeneration in Caenorhabditis elegans
por: Cao, Pengxiu, et al.
Publicado: (2010)

Optogenetic Rescue of Locomotor Dysfunction and Dopaminergic Degeneration Caused by Alpha-Synuclein and EKO Genes
por: Qi, Cheng, et al.
Publicado: (2017)

Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases
por: Melki, Ronald
Publicado: (2015)

Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies
por: Gámez-Valero, Ana, et al.
Publicado: (2018)

A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies
por: Ryskalin, Larisa, et al.
Publicado: (2018)

Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective
por: Knecht, Luisa, et al.
Publicado: (2022)

Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques
por: Sucunza, Diego, et al.
Publicado: (2021)

The Role of Glia in Alpha-Synucleinopathies
por: Fellner, Lisa, et al.
Publicado: (2012)

Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice
por: Lee, He-Jin, et al.
Publicado: (2011)

Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies
por: Corbillé, Anne-Gaëlle, et al.
Publicado: (2016)

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
por: Magalhães, Pedro, et al.
Publicado: (2022)

In Silico Evaluation of the Potential Association of the Pathogenic Mutations of Alpha Synuclein Protein with Induction of Synucleinopathies
por: Elnageeb, Mohamed E., et al.
Publicado: (2023)

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
por: Van Rompuy, Anne-Sophie, et al.
Publicado: (2015)

The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
por: Kelly, Rachel, et al.
Publicado: (2021)

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
por: Grotemeyer, Alexander, et al.
Publicado: (2023)

Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis
por: Killinger, Bryan A., et al.
Publicado: (2023)

Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease
por: Kaul, Tiffany, et al.
Publicado: (2011)

Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
por: Oueslati, Abid
Publicado: (2016)

Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats
por: Gubinelli, F., et al.
Publicado: (2022)

Pure Autonomic Failure-A Localized Alpha Synucleinopathy with a Potential for Conversion to More Extensive Alpha Synucleinopathies
por: Bhattacharjee, Shakya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhpr8qdevsq5aajq0378sv140t